



SAMI GEORGE DIAB, M.D.

OFFICE ADDRESS:

Rocky Mountain Cancer Centers-Aurora
1700 South Potomac St.
Aurora, CO 80012
Phone: (303) 418-7600
FAX: (303) 750-3137

DATE AND PLACE OF BIRTH:

July 1, 1965, Damascus, Syria

CITIZENSHIP:

U.S. Naturalized Citizen, April 1995

EDUCATION:

1982 French School of Damascus (General Science Degree)
1988 M.D. Medical School, Damascus University, Damascus, Syria

POSTDOCTORAL TRAINING:

06/90-06/93 Internship and Residency in Internal Medicine, Wayne State University, Detroit, Michigan
07/93-07/94 Fellow in Medical Oncology, UT M.D. Anderson Cancer Center, Houston, Texas
08/94-07/95 Fellow in Medical Oncology, University of Texas Health Science Center at San Antonio
08/95-08/96 Resident in Radiation Oncology, University of Texas Health Science Center at San Antonio

HOSPITAL STAFF AND ACADEMIC APPOINTMENTS:

6/99-present Rocky Mountain Cancer Centers-Aurora, Colorado
9/98-6/99 Chief, Medical Oncology, Audie Murphy Veterans Hospital San Antonio, Texas
8/96-6/99 Associate Director, Fellowship Program, Department of Medicine, Division of Medical Oncology, The University of Texas Health Science Center, San Antonio, Texas
8/96-6/99 Assistant Professor, Department of Medicine, The University of Texas Health Science Center, San Antonio, Texas
8/96-6/99 Staff Physician, Medicine Service, Audie L. Murphy Division, South Texas Veterans Health Care System, Department of Veterans Affairs, San Antonio, Texas

LICENSURE AND CERTIFICATION:

1993 ABIM, Internal Medicine, #151059
1995 ABIM, Medical Oncology, #151059
1992 Michigan License, Permit #2998956

1994 Texas License, Permit #17466
1996 North Carolina License, Permit # 96-00514
1999 Colorado License

MEMBERSHIPS:

1990 American College of Physicians
1994 American Association for Cancer Research
1998 American Association for the Advancement of Science
1998 American Society of Clinical Oncology

COMMITTEES:

4/97-6/99 Executive Breast Committee, South West Oncology Group
7/97-6/99 Cancer Control Committee, The University of Texas Health
Science Center at San Antonio, San Antonio, Texas
1/98-6/99 Institutional Review Board, The University of Texas Health
Science Center at San Antonio, San Antonio, Texas
7/96-6/99 Credentials Committee, Cancer Therapy & Research Center,
San Antonio, Texas

BENCH RESEARCH EXPERIENCE:

7/94-9/95 Molecular Biology of Estrogen Receptor: Identification of ER associated proteins
using Yeast-Two-Hybrid system.

MANUSCRIPT REVIEWER:

Journal of Clinical Oncology
Breast Cancer Research and Treatment
Investigational New Drugs
Anti-Cancer Drugs
International Journal of Cancer

PUBLICATIONS:

1. Diab SG, Castles CG, Fuqua SAW. Role of Altered Estrogen Receptors in Breast Cancer. In Vedeckis WV, (ed.): Hormone and Cancer. Birkhauser, Boston 1996. Pp 261-281, 1996
2. Diab SG, Yu Y-Y, Hilsenbeck SG, Allred DC, and Elledge RM. WAF1/CIP1 Protein Expression In Human Breast Cancer. Breast Cancer Research and Treatment 43: 99-1031 1997
3. Diab SG, Hilsenbeck S, De Moor C, Clark GM, Osborne CK, Ravdin P, and Elledge RM. Radiation Therapy and Survival in Breast Cancer Patients with 10 or More Positive Auxiliary Lymph Nodes Treated with Mastectomy. Journal of Clinical Oncology, 16: 1655-1660, 1998
4. Sami G. Diab, Sharyn D. Baker, Amita Joshi, Howard A. Burris, Patrick W. Cobb, Miguel A. Villalona-Calero, S. Gail ckhardt, Geoffrey R. Weiss, Gladys I. Rodriguez, Ronald Drenkler, Maura Kraynak, Lisa Hammond, Michael Finizio, Daniel D. Von Hoff, and Eric K. Rowinsky. A Phase I and Pharmacokinetic Study of Losoxantrone and Paclitaxel in Patients with Advanced Solid Tumors. Clinical Cancer Research, 5: 299-308, 1999
5. Diab SG, Clark GM, Libby A, Allred DC, Osborne CK, and Elledge RM. Tumor Characteristics and Clinical Outcome of Tubular and Mucinous; Breast Carcinoma. Journal of Clinical Oncology 17: 1442-1448, 1999

6. Sami G. Diab, Susan G. Hilsenbeck, Elzbieta Izbicka, Steve Weitman and Daniel D. Von Hoff. Significant Activity of a Novel Cytotoxic Agent, LY295501, Against a Wide Range of Tumors in the Human Tumor Cloning System. *AntiCancer Drugs*, 10: 303-307, 1999
7. Sami G. Diab, Richard M. Elledge, Gary M. Clark. Tumor Characteristics and Clinical Outcome of Elderly Patients with Breast Cancer. *Journal of the National Cancer Institute* 92, 550-556, 2000
8. Sharma S, and Diab SG. Are We Just Specialists or Is It Time For Us to Broaden Our Horizons in Treating The Cancer Patient? *Seminars in Oncology*. 24(5), 1997
9. Britten CD, Rowinsky EK, Baker SD, Agarwala SS, Eckardt JR, Barrington R, Diab SG, Hammond LA, Johnson T, Villalona-Calero M, Fraass U, Statkevich P, Von Hoff DD, Eckhardt SG. A Phase I and pharmacokinetic study of temozolomide and cisplatin in patients with advanced solid malignancies. *Clin Cancer Res*. 1999 Jul;5(7):1629-37.
10. Hidalgo M, Villalona-Calero MA, Eckhardt SG, Drenkler RL, Rodriguez G, Hammond LA, Diab SG, Weiss G, Garner AM, Campbell E, Davidson K, Louie A, O'Neil A von Borstel R, Von Hoff DD, Rowinsky EK. Phase I and pharmacologic study of PN401 and fluorouracil in patients with advanced solid malignancies. *J Clin Oncol* 2000 Jan; 18(1):167-77

PRESENTATIONS AT NATIONAL AND INTERNATIONAL MEETINGS:

- Radiation therapy improves survival by decreasing local failure in breast cancer patients with 10 or more positive auxiliary lymph nodes treated with mastectomy. SG Diab, CA de Moor, GM Clark, CK Osborne, PM Ravdin, RM Elledge. Meeting of the American Society of Medical Oncology, Denver, 1997
- Does radiotherapy have an impact on systemic relapse. G Clark, SG Diab, S Hilsenbeck. Presented at the 20th International Congress of Chemotherapy. Sidney, Australia, 7/97.

Abstracts:

Annual San Antonio Breast Cancer Symposium 1996 and 1997

Diab SG, deMoor CA, Clark GM, Elledge RM. Adjuvant Local Radiation Therapy and Survival in Breast Cancer Patients with 10 or More Positive Lymph Nodes. Presented at the 19th Annual San Antonio Breast Cancer Symposium, 1996

Diab SG, Clark GM, Libby A, Allred DC, Osborne CK, and Elledge RM. Tumor Characteristics and Clinical Outcome of Tubular and Mucinous Breast Carcinoma. Presented at the 20th Annual San Antonio Breast Cancer Symposium, 1997

American Society of Clinical Oncology meeting, 1997

SG Diab, CA de Moor, GM Clark, CK Osborne, PM Ravdin, RM Elledge. Radiation therapy improves survival by decreasing local failure in breast cancer patients with 10 or more positive auxiliary lymph nodes treated with mastectomy. (oral presentation).

SG Eckhardt, Y Atkins, SS Agarwala, 3 Eckardt, S. Diab, M Dugan, P Reidenberg, P Statkevich, M Kraynak, DD Von Hoff and EK with Cisplatin (CDDP) in Patients with Advanced Cancer. Cancer Therapy and Research Center, San Antonio, TX, University of Pittsburgh, Pittsburgh, PA and Schering-Plough, Kenilworth, NJ. American Society of Clinical Oncology meeting, 1998

S Diab, C Britten, G Eckhardt, L Hammond, R Elledge, L Siu, S Sharma, M Hidalgo, C Aylesworth, B Razvillas, M Kraynak, S Baker, R Smith, S Averbuch, D Von Hoff, and E Rowinsky: Phase I and Pharmacokinetic (PK) Study of the Nonpolyglutarnated Thymidylate Synthase (TS) Inhibitor ZD9331 Given as a 30 Minute Infusion Every 3 Weeks. Cancer Therapy and Research Center, University of Texas Health Science Center, Brooke Army Medical Center, San Antonio, TX and Zeneca Pharmaceuticals, Wilmington, DE. (poster discussion)

P Khoury, M Villalona-Calero, J Blum, S Diab, R Elledge, M Kraynak, J Moczygema, P Kromelis, I Morales, C Brown, T Griffin, D Von Hoff, E Rowinsky: Phase I Study of Capecitabine in Combination with Paclitaxel in Patients with Previously Treated Metastatic Breast Cancer. The University of Texas Health Science Center and Cancer Therapy & Research Center, San Antonio, TX, PRN Research, Dallas TXS, and Hoffman-La Roche LTD. Nutley, New Jersey.

L Hammond, M Villalona-Calero, SG Eckhardt, R Drengler, C Aylesworth, T Johnson, M Hidalgo, G Rodriguez, S Diab, P Monroe, D Thornton, D Von Hoff, and E Rowinsky. A Phase I and Pharmacokinetic (PK) Study of the Multitargeted Antifol (MTA) LY231514 with Folic Acid. Cancer Therapy and Research Center and Brooke Army Medical Center, San Antonio, TX and Eli Lilly Company, Indianapolis, IN. Presented at the American Society of Clinical Oncology Meeting, 1998

10th NCI-EORTC Symposium on New Drugs in Cancer Therapy, Amsterdam, 1998

S Diab, SD Baker, L Hammond, M Villalona-Calero, SG Eckhardt, C Tin-U, G Weiss, M Kraynak, C AN/lesworth, L Smith, G Rodriguez, R Drengler, R Patil, L Siu, M Rothenberg, L Smetzer, E Nyhart, AM Sorniolof D Von Hoff, and E Rowinsky. Phase I and Pharmacokinetic (PK) Study of the Diarylsulfonylurea LY295501 Administered as a single oral dose weekly for 3 weeks every 4 weeks. Cancer Therapy and Research Center, University of Texas Health Science Center, Brooke Army Medical Center, San Antonio, TX; Eli Lilly and Company, Indianapolis, IN

M Villalona-Calero, J Blum, S Diab, R Elledge, P Khoury, M Kraynak, J Moczygema, P Kromelis, K Impellizeri, T Griffin, D Von Hoff, E rowinsky. Phase I Study of Capecitabine in Combination with Pacfitaxel in Patients with Previously Treated Metastatic Breast Cancer. Cancer Therapy and Research Center, San Antonio, TX, PRN Research, Dallas TX, and Hoffman-La Roche, Nutley, NJ

L Hammond, SD Baker, M Villalona-Calero, SG Eckhardt, R Drengler, C Aylesworth, T Johnson, M Hidalgo, G Rodriguez, S Diab, P Monroe, D Thornton, R Johnson, D Von Hoff, and E Rowinsky. A Phase I and Pharmacokinetic (PK) Study of the Multitargeted Antifol (MTA) LY231514 with Folic Acid (FA). Cancer Therapy and Reserach Center and Brooke Army Medical Center, San Antonio TX, and Eli Lilly Company Indianapolis, IN

M Hidalgo, MA Villalona-Calero, C Britten, L Siu, R Drengler, L Hammond, S Diab, E Campbell, A Louie, I ONeil, D Von Hoff, and E Rowinsky. A Phase I and Pharmacokinetic (PK) Study of PN401 as a Rescue Agent for Escalating Doses of 5-Fluorouracil (5-FU) in Patients

(PTS) with Cancer. Cancer Therapy and Research Center, San Antonio TX, and Pro-Neuron, Inc., Gaithersburg, MD., to be presented at 10th NCI-EORTC Symposium on New Drugs in Cancer Therapy, June 16-19, 1998

CD Britten, EK Rowinsky, SS Agarwala, SD Baker, I Eckardt, S Diab, M Dugan, P Reidenberg, P Statkevich, A Marco, A Loomba, K Forral, M Kraynak, DD Von Hoff, and SG Eckhardt. A Phase I Safety and Pharmacokinetic (PK) Study of Temozolomide in Combination with Cisplatin. Cancer Therapy and Research Center, San Antonio TX, University of Pittsburgh, Pittsburgh PA, and ScheringPlough, Kenilworth NJ. American Society of Clinical Oncology meeting, 1999

SG Diab, RM Elledge, and GM Clark. Favorable biological characteristics and clinical outcome in elderly patients with invasive ductal carcinoma (IDC) of the breast. (poster discussion)

W Tan, C. Tin-U, M Villalona, L Ochoa, M Kalidas, R Drengler, P Khoury, T Herman, A W Vally, B Brady, E Rowinsky, S Diab. Phase I study of weekly paclitaxel in combination with daily cisplatin and radiation in locally advanced head and neck and non-small cell lung carcinoma and esophageal carcinoma.

R Sun Young, SG Diab, C Britten, G Eckhardt, L Hammond, R Elledge, L Siu, S Sharma, M Hidalgo, C Aylesworth, B Razvillas, M Kraynak, S Baker, R Smith, S Averbuch, D Von Hoff, and E Rowinsky. Determination of the Variables affecting the Clearance of the Novel Thymidylate Synthase (TS) Inhibitor ZD9331

E Rowinsky, T Johnson, C Geyer, SG Eckhardt, L Smetzer, J Coyle, R Drengler, S Diab, IR De Jager, and D Von Hoff. DX-8951f, a hexacyclic captothecin (CPT) analog on a daily x 5 schedule: a phase I and pharmacokinetic study.

T Johnson, L Hammond, R Johnson, R Drengler, SG Eckhardt, J neumanitis, M Villalona, T Williams, S Diab, J Walling, C Simmon, D Von Hoff, and E Rowinsky. Phase I and pharmacokinetic study of the multitargeted Antifol LY231514 (MTA) in combination with irinotecan (CPT-11).

Miscellaneous meetings

Andersen 3, Shelly C, Diab S. Receptor-Independent Augmentation of Cytokine-Induced Endothelial Cell Tissue Factor Production by Flavone Acetic Acid may Promote Vascular Thrombosis. Presented at the American Society of Hematology Meeting, 1991

Andersen J, Shelly C, Diab S. Flavone Acetic Acid Augments Cytokine-Stimulated Endothelial Cell Tissue Factor Production by a Receptor-Independent Mechanism. Presented at Symposium on the Molecular Biology of Endothelial Cells, Keystone, 1992

Diab S, Shelly C, Andersen J. Cytokine-Stimulated Human Endothelial Cells Bind IGG from Patients with Thrombotic Thrombocytopenic Purpura (TTP) and Hemolytic Uremic Syndrome (HUS). Presented at American College of Physicians National Meeting, 1992

Diab SG, deMoor CA, Clark GM, Elledge RM. Prognostic Factors in Breast Cancer Patients with 10 or more Positive Lymph Nodes. Abstract. Presented at 5th Annual Symposium on Cancer Research, San Antonio, 1995